Article Text

Download PDFPDF
Breast cancer prognosis and P-cadherin expression: systematic review and study-level meta-analysis
  1. Runzhi Qi1,
  2. Jinyin Lin2,
  3. Shuntai Chen3,
  4. Juling Jiang1,
  5. Xing Zhang1,
  6. Bo Yao4,
  7. Honggang Zheng1,
  8. Zhichao Jin5,
  9. Yuan Yuan6,
  10. Wei Hou1,
  11. Baojin Hua1 and
  12. Qiujun Guo1
  1. 1Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
  2. 2Administrative Department, Beijing Tongren Hospital Affiliated to Capital Medical University, Beijing, China
  3. 3Beijing University of Chinese Medicine, Beijing, China
  4. 4First Clinical Medical College, Heilongjiang University of Chinese Medicine, Heilongjiang, China
  5. 5Department of Oncology, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China
  6. 6Department of Pneumology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
  1. Correspondence to Dr Qiujun Guo, Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China; drguoqiujun{at}126.com; Professor Baojin Hua, Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China; huabaojinxs{at}126.com

Abstract

Objective P-cadherin can act both as a tumour suppressor and an oncogene. The clinical prognostic value of P-cadherin overexpression in breast cancer (BC) remains unclear. We conducted a study-level meta-analysis to determine whether P-cadherin expression can help predict prognosis in BC.

Methods A systematic literature search was performed to review eligible studies and clarify the relationship between P-cadherin overexpression and overall survival (OS), disease-free survival (DFS), pathological features, molecular subtypes and molecular phenotypes in BC.

Results Thirty-one studies including 12 332 patients were included. P-cadherin overexpression was correlated with significantly worse OS (HR=1.77, p<0.00001) and DFS (HR=1.96, p<0.00001) than P-cadherin-negative. P-cadherin overexpression could lead to high histological grade (OR=3.33, p<0.00001) and lymph node metastasis (OR=1.62, p<0.00001). Moreover, P-cadherin overexpression was associated with low odds of the luminal A subtype and high odds of the human epidermal growth factor receptor-2 (HER2)-positive and triple-negative subtypes. P-cadherin expression led to low expression of oestrogen and progesterone receptor (OR=0.37 and OR=0.36, respectively, both p<0.00001) and high expression of HER2 (OR=2.31, p<0.00001), Ki-67 (OR=2.79, p<0.00001), epidermal growth factor receptor (OR=5.85, p<0.00001) and cytokeratin 5/6 (OR=6.79, p<0.00001).

Conclusions P-cadherin was found to be associated with invasiveness and metastasis. P-cadherin expression can probably be a useful biomarker for predicting poor survival and may act as an independent prognostic predictor.

  • cancer
  • breast
  • prognosis
View Full Text

Statistics from Altmetric.com

Footnotes

  • RQ, JL, SC, JJ and XZ contributed equally.

  • BH and QG contributed equally.

  • Contributors QG and RQ contributed to study concepts. BH, JL, QG, RQ, SC, JJ and XZ contributed to study design. RQ, SC, JJ, BY and XZ contributed to data acquisition. BH, RQ, JL and QG contributed to quality control of data and algorithms. RQ, JL, BY, YY, QG, SC and ZJ contributed to data analysis and interpretation. RQ, SC, JJ and BY contributed to statistical analysis. RQ, JJ, SC, BY, QG, BH and XZ contributed to manuscript preparation. RQ, JJ, SC, ZJ, QG, YY, BH and XZ contributed to manuscript editing. YY, BH and ZJ contributed to manuscript review. All authors gave final approval for submission of the manuscript.

  • Funding This study was funded by Specialized Training for Outstanding Young Scientific and Technological Talents (Innovation) of the China Academy of Chinese Medical Sciences.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.